Clinical Trial: Non-alcoholic Fatty Liver Disease and Its Treatment
Study Status: Completed
Recruit Status: Completed
Condition: NAFLD
Study Type: Interventional
Official Title: Effect of DPP-4I and Related Treatment on Non-alcoholic Fatty Liver Disease
Brief Summary:
Dipeptidyl peptidase-4 inhibitors (DPP-4I), key regulators of the actions of incretin hormones, exert anti-hyperglycemic effects in type 2 diabetes mellitus (T2DM) patients. A major unanswered question concerns the potential ability of DPP-4I to improve intrahepatic lipid (IHL) content in nonalcoholic fatty liver disease (NAFLD) patients. The aim of this study was to evaluate the effects of sitagliptin on IHL in NAFLD patients.
Read more